这项研究的目的是开发一种含有吗替麦松呋酯（MMF）的持续释放清漆（SRV）用于鼻窦支架（SNS），以减少鼻窦腔内粘膜炎症。涂有SRV-MMF或SRV安慰剂的SNS段每天在37℃的新鲜DMEM中孵育20天。收集的DMEM上清液的免疫抑制活性被测试用于小鼠RAW 264.7巨噬细胞对脂多糖（LPS）诱导的细胞因子肿瘤坏死因子α（TNFα）、白细胞介素（IL）-10和IL-6的分泌能力。分别用酶联免疫吸附分析（ELISA）来测定细胞因子水平。我们发现，从涂有MMF的SNS中释放出的每日量足以显著抑制巨噬细胞分泌LPS诱导的IL-6和IL-10，分别持续至第14天和第17天。相比于SRV安慰剂涂层的SNS，SRV-MMF对LPS诱导的TNFα分泌仅有轻微的抑制作用。总之，涂层SNS与SRV-MMF提供了至少2周的MMF持续释放，维持足够的水平抑制炎症性细胞因子的释放。因此，这一技术平台有望在手术后愈合期间提供抗炎益处，并在未来治疗慢性鼻窦炎中发挥重要作用。

The aim of the study was to develop a sustained-release varnish (SRV) containing mometasone furoate (MMF) for sinonasal stents (SNS) to reduce mucosa inflammation in the sinonasal cavity. The SNS' segments coated with SRV-MMF or an SRV-placebo were incubated daily in a fresh DMEM at 37 °C for 20 days. The immunosuppressive activity of the collected DMEM supernatants was tested on the ability of mouse RAW 264.7 macrophages to secrete the cytokines' tumor necrosis factor α (TNFα) and interleukin (IL)-10 and IL-6 in response to lipopolysaccharide (LPS). The cytokine levels were determined by respective Enzyme-Linked Immunosorbent Assays (ELISAs). We found that the daily amount of MMF released from the coated SNS was sufficient to significantly inhibit LPS-induced IL-6 and IL-10 secretion from the macrophages up to days 14 and 17, respectively. SRV-MMF had, however, only a mild inhibitory effect on LPS-induced TNFα secretion as compared to the SRV-placebo-coated SNS. In conclusion, the coating of SNS with SRV-MMF provides a sustained delivery of MMF for at least 2 weeks, maintaining a level sufficient for inhibiting pro-inflammatory cytokine release. This technological platform is, therefore, expected to provide anti-inflammatory benefits during the postoperative healing period and may play a significant role in the future treatment of chronic rhinosinusitis.